PRR7

Across TCGA pan-cancer cohorts, PRR7 RNA is linked to patient survival in 26 of 34 cancer types, making it the most broadly survival-associated PRR7 data layer compared with 1 for mutation status.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher PRR7 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated PRR7 expression acts as an unfavorable survival marker, although some lineages such as ESCA and READ show a favorable association.

LIHC, UVM, and MESO are the cancer types where PRR7 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	All	0.584	0.782	<.001	81	view →
UVM	DFS	Quartile	II,III,IV	0.411	0.817	.005	79	view →
MESO	OS	Tertile	All	0.415	0.750	<.001	72	view →
UCS	OS	Tertile	III,IV	0.399	0.809	.007	48	view →
LGG	DFS	Median	All	0.646	0.822	<.001	38	view →
ACC	DFS	Median	All	0.332	0.779	<.001	36	view →
LAML	DFS	Median	All	0.247	0.490	.001	32	view →
KIRC	OS	Tertile	All	0.587	0.754	.008	23	view →
PRAD	DFS	Median	All	0.715	0.875	<.001	18	view →
LUAD	DFS	Tertile	All	0.603	0.747	.011	17	view →
SARC	OS	Median	All	0.620	0.828	.001	17	view →
THCA	OS	Median	III,IV	0.904	0.980	.021	16	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 26 lineages.

PRR7–LIHC (OS)

Open the LIHC breakdown →